Randomized Phase II Study of Weekly Paclitaxel plus Carboplatin Versus Biweekly Paclitaxel plus Carboplatin for Patients with Previously Untreated Advanced Non-Small Cell Lung Cancer.
Adenocarcinoma of Lung
/ drug therapy
Antineoplastic Combined Chemotherapy Protocols
/ therapeutic use
Carboplatin
/ administration & dosage
Carcinoma, Non-Small-Cell Lung
/ drug therapy
Carcinoma, Squamous Cell
/ drug therapy
Female
Follow-Up Studies
Humans
Lung Neoplasms
/ drug therapy
Male
Middle Aged
Paclitaxel
/ administration & dosage
Prognosis
Survival Rate
Journal
The oncologist
ISSN: 1549-490X
Titre abrégé: Oncologist
Pays: England
ID NLM: 9607837
Informations de publication
Date de publication:
11 2019
11 2019
Historique:
received:
08
05
2019
accepted:
08
07
2019
pubmed:
25
7
2019
medline:
1
8
2020
entrez:
24
7
2019
Statut:
ppublish
Résumé
This clinical trial, evaluating the efficacy and safety of a carboplatin plus paclitaxel regimen in a biweekly or weekly schedule instead of the more toxic 3-weekly administration, showed that the weekly regimen was better in efficacy than the biweekly regimen, with mild toxicities, for patients with non-small cell lung cancer (NSCLC).The weekly carboplatin plus paclitaxel regimen could be considered as an alternative to the 3-weekly regimen in Japanese patients with NSCLC. Combination therapy comprising carboplatin (C) and paclitaxel (P) is the most commonly used regimen for the treatment of advanced non-small cell lung cancer (NSCLC). Common toxicities associated with the regimen, such as neuropathy and myelosuppression, cause its discontinuation. In the present study, we conducted a clinical trial evaluating the efficacy of biweekly (B) and weekly (W) PC therapy to identify the appropriate chemotherapy schedule for Asian patients. Chemonaive patients with IIIB/IV NSCLC and a performance status of 0-1 were randomly assigned to a biweekly regimen (paclitaxel 135 mg/m A total of 140 patients were enrolled in the study. The objective response rates (ORRs) were 28.1% (B) and 38.0% (W). The most common toxicity was neutropenia, with incidence rates of 62.0% (B) and 57.8% (W). Progression-free survivals (PFSs) were 4.3 months (B) and 5.1 months (W), and overall survival durations were 14.2 months (B) and 13.3 months (W). The ORR and PFS in the weekly regimen were better than those in the biweekly schedule, although a statistical difference was not observed. The toxicity profile was generally mild for both regimens. The weekly CP regimen was suitable to be considered as an alternative to the current 3-weekly regimen in NSCLC treatment.
Sections du résumé
LESSONS LEARNED
This clinical trial, evaluating the efficacy and safety of a carboplatin plus paclitaxel regimen in a biweekly or weekly schedule instead of the more toxic 3-weekly administration, showed that the weekly regimen was better in efficacy than the biweekly regimen, with mild toxicities, for patients with non-small cell lung cancer (NSCLC).The weekly carboplatin plus paclitaxel regimen could be considered as an alternative to the 3-weekly regimen in Japanese patients with NSCLC.
BACKGROUND
Combination therapy comprising carboplatin (C) and paclitaxel (P) is the most commonly used regimen for the treatment of advanced non-small cell lung cancer (NSCLC). Common toxicities associated with the regimen, such as neuropathy and myelosuppression, cause its discontinuation. In the present study, we conducted a clinical trial evaluating the efficacy of biweekly (B) and weekly (W) PC therapy to identify the appropriate chemotherapy schedule for Asian patients.
METHODS
Chemonaive patients with IIIB/IV NSCLC and a performance status of 0-1 were randomly assigned to a biweekly regimen (paclitaxel 135 mg/m
RESULTS
A total of 140 patients were enrolled in the study. The objective response rates (ORRs) were 28.1% (B) and 38.0% (W). The most common toxicity was neutropenia, with incidence rates of 62.0% (B) and 57.8% (W). Progression-free survivals (PFSs) were 4.3 months (B) and 5.1 months (W), and overall survival durations were 14.2 months (B) and 13.3 months (W).
CONCLUSION
The ORR and PFS in the weekly regimen were better than those in the biweekly schedule, although a statistical difference was not observed. The toxicity profile was generally mild for both regimens. The weekly CP regimen was suitable to be considered as an alternative to the current 3-weekly regimen in NSCLC treatment.
Identifiants
pubmed: 31332099
pii: theoncologist.2019-0513
doi: 10.1634/theoncologist.2019-0513
pmc: PMC6853129
doi:
Substances chimiques
Carboplatin
BG3F62OND5
Paclitaxel
P88XT4IS4D
Banques de données
UMIN-CTR
['UMIN000036556']
Types de publication
Clinical Trial, Phase II
Journal Article
Randomized Controlled Trial
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
1420-e1010Informations de copyright
© AlphaMed Press; the data published online to support this summary is the property of the authors.
Références
N Engl J Med. 2009 Sep 3;361(10):947-57
pubmed: 19692680
J Clin Oncol. 2009 Jul 20;27(21):3540-6
pubmed: 19470925
N Engl J Med. 2006 Dec 14;355(24):2542-50
pubmed: 17167137
J Clin Oncol. 2001 Jul 1;19(13):3210-8
pubmed: 11432888
Am J Epidemiol. 2007 Jun 1;165(11):1280-6
pubmed: 17369610
J Clin Oncol. 2008 Jan 1;26(1):60-5
pubmed: 18165641
N Engl J Med. 2010 Jun 24;362(25):2380-8
pubmed: 20573926
N Engl J Med. 2002 Jan 10;346(2):92-8
pubmed: 11784875
Cancer Chemother Pharmacol. 2003 Jul;52(1):67-72
pubmed: 12743738
Ann Oncol. 2005 Jul;16(7):1069-75
pubmed: 15860487
Jpn J Clin Oncol. 2012 Mar;42(3):239-40
pubmed: 22375029
Ann Oncol. 2007 Feb;18(2):317-23
pubmed: 17079694
J Clin Oncol. 2003 Aug 1;21(15):2933-9
pubmed: 12885812
Cancer Chemother Pharmacol. 2006 Sep;58(3):368-73
pubmed: 16395589
Lancet Oncol. 2005 Sep;6(9):669-77
pubmed: 16129367
Jpn J Clin Oncol. 2013 May;43(5):492-507
pubmed: 23493744
J Clin Oncol. 2008 Jan 20;26(3):468-73
pubmed: 18202422
Lung Cancer. 2012 Jun;76(3):362-7
pubmed: 22244743
Cancer. 2009 Jan 1;115(1):119-27
pubmed: 19090009
Ann Oncol. 2000 Jul;11(7):799-805
pubmed: 10997806
Br J Cancer. 2009 Nov 3;101(9):1537-42
pubmed: 19862000